Safety and efficacy of the cell-associated vaccine prepared by an attenuated infectious laryngotracheitis virus.
The safety and efficacy of the cell-associated (C-A) vaccine prepared by chicken embryo fibroblast (CEF) cells infected with the tissue-culture-modified strain of infectious laryngotracheitis (ILT) virus were studied in chickens. Over seventy percent of chickens inoculated with the C-A vaccine by the subcutaneous (S.C.) or intramuscular (I.M.) route at 1 day of age was protected against challenge with a virulent strain of ILT virus without any clinical signs. Chickens vaccinated with the C-A vaccine at 1 day of age acquired immunity within 6 days after vaccination, and the protection rate maintained more than 60% until 10 weeks post-vaccination. The C-A vaccine was invariably effective for chickens at various age. There was no evidence that the development of immunity was hindered by further vaccination with Newcastle disease and infectious bronchitis combined live vaccine. In addition, the C-A vaccine was safe when chickens were inoculated with 10 doses. In the field trials of the C-A vaccine, no adverse reaction was observed, and over 65% of vaccinated chickens was protected against the challenge of the virulent ILT virus at 8 weeks after vaccination.
Taneno
A
A
Department of Animal Products, Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan.
Honda
T
T
Sakai
E
E
Kawai
T
T
Tokuyama
Y
Y
Eto
M
M
D000367:Age Factors; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002642:Chick Embryo; D002645:Chickens; D004306:Dose-Response Relationship, Immunologic; D006385:Hemagglutination Inhibition Tests; D006566:Herpesviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D001352:Herpesvirus 1, Gallid / Q000276:immunology*; D001351:Infectious bronchitis virus / Q000276:immunology; D009522:Newcastle disease virus / Q000276:immunology; D011201:Poultry Diseases / Q000517:prevention & control*; D014611:Vaccination / Q000662:veterinary; D014613:Vaccines, Attenuated / Q000009:adverse effects; D014765:Viral Vaccines / Q000009:adverse effects
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines